Immunotherapy for head and neck cancer: Advances and deficiencies

Anti-Cancer Drugs

Volumn 22, Issue 7, 2011, Pages 674-681

  De Costa, Anna Maria ^a,b   Young, M Rita I ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

head and neck cancer; head and neck squamous cell carcinomas; immunosuppression; immunotherapy; suppressor cells; tumor antigens

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GAMMA INTERFERON; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; IPILIMUMAB; IRINOTECAN; NIMOTUZUMAB; TICILIMUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS CANCER; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LEUKEMIA; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY;

EID: 79960465036     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328340fd18     Document Type: Review

References (85)

1. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010; 18:1039-1060.
2. Gotte K, Usener D, Riedel F, Hormann K, Schadendorf D, Eichmuller S. Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes. Acta Otolaryngol 2002; 122:546-552. (Pubitemid 34913438)
3. Young MR, Neville BW, Chi AC, Lathers DM, Boyd GM, Day TA. Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma. Cancer Immunol Immunother 2007; 56:1077-1086. (Pubitemid 46675292)
4. Beckhove P, Warta R, Lemke B, Stoycheva D, Momburg F, Schnolzer M, et al. Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J Clin Invest 2010; 120:2230-2242.
5. Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, et al. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 2006; 5:1218-1225. (Pubitemid 44772241)
6. Rabassa ME, Croce MV, Pereyra A, Segal-Eiras A. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. BMC Cancer 2006; 6:253.
7. Chow V, Yuen AP, Lam KY, Ho WK, Wei WI. Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck 2001; 23:286-291. (Pubitemid 32234105)
8. + B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro-and hypopharyngeal carcinoma. BMC Cancer 2009; 9:292.
9. + gd T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 2008; 14:4232-4240.
10. Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993; 53:5654-5662. (Pubitemid 23360267)
11. Dadian G, Riches PG, Henderson DC, MacLennan K, Lorentzos A, Moore J, et al. Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 1993; 29B:29-34. (Pubitemid 23068393)
12. De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 2002; 95:90-97. (Pubitemid 34743486)
13. Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant interleukin-2 and a-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer 1993; 71:2326-2331. (Pubitemid 23087775)
14. Bazarbashi S, Rahal M, Raja MA, El Weshi A, Pai C, Ezzat A, et al. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-a in the treatment of advanced esophageal carcinoma. Chemotherapy 2002; 48:211-216.
15. Richtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg 1990; 116:1271-1277. (Pubitemid 20362054)
16. Van Herpen CM, Van der Voort R, Van der Laak JA, Klasen IS, De Graaf AO, Van Kempen LC, et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 2008; 123:2354-2361.
17. Van Herpen CM, Looman M, Zonneveld M, Scharenborg N, De Wilde PC, Van de Locht L, et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004; 10:2626-2635. (Pubitemid 38509135)
18. Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, et al. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 2010. [Epub ahead of print]
19. Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 2007; 30:624-633. (Pubitemid 47229697)
20. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem 2010; 17:3297-3302.
21. Pasquali S, Mocellin S. The anticancer face of interferon a (IFN-a): from biology to clinical results, with a focus on melanoma. Curr Med Chem 2010; 17:3327-3336.
22. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000; 18:1614-1621. (Pubitemid 30220539)
23. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70:4297-4309.
24. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 2010; 16:2474-2482.
25. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, et al. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs 2010. [Epub ahead of print]
26. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208. (Pubitemid 41079832)
27. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68:4998-5003.
28. Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 2005; 46:620-633. (Pubitemid 41716407)
29. Dean NR, Knowles JA, Helman EE, Aldridge JC, Carroll WR, Magnuson JS, et al. Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Anticancer Drugs 2010; 21:861-867.
30. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64:5355-5362. (Pubitemid 39006556)
31. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25: 4557-4561. (Pubitemid 350035312)
32. Lorenzen S, Schuster T, Porschen R, Al Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20:1667-1673.
33. Chen LF, Cohen EEW, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010; 16:2489-2495.
34. Riechelmann H, Wiesneth M, Schauwecker P, Reinhardt P, Gronau S, Schmitt A, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007; 56:1397-1406. (Pubitemid 47024704)
35. To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000; 126:1225-1231.
36. Herold-Mende C, Karcher J, Dyckhoff G, Schirrmacher V. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv Otorhinolaryngol 2005; 62:173-183. (Pubitemid 40014315)
37. Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. J Am Med Assoc 2009; 302:781-786.
38. + HNSCC. Head Neck 2009; 31:911-918.
39. Ferris DG, Waller JL, Miller J, Patel P, Price GA, Jackson L, et al. Variables associated with human papillomavirus (HPV) vaccine acceptance by men. J Am Board Fam Med 2009; 22:34-42.
40. Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, et al. Large randomized study of thymosin a1, interferon a, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010; 28:1780-1787.
41. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleukin (interleukin 2) and IFN-a2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009; 15:4986-4992.
42. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
43. Victora GD, Socorro-Silva A, Volsi EC, Abdallah K, Lima FD, Smith RB, et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 2009; 16:598-608.
44. Oddone N, Morgan GJ, Palme CE, Perera L, Shannon J, Wong E, et al. Metastatic cutaneous squamous cell carcinoma of the head and neck: the immunosuppression, treatment, extranodal spread, and margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer 2009; 115:1883-1891.
45. Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, et al. Overexpression of transforming growth factor b1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004; 64:4405-4410. (Pubitemid 38856909)
46. Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther 2004; 3:847-852. (Pubitemid 41351049)
47. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69:3105-3113.
48. Minakuchi R, Wacholtz MC, Davis LS, Lipsky PE. Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol 1990; 145:2616-2625. (Pubitemid 20374587)
49. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146:108-113.
50. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Maramatsu M, Li X-F, et al. Transforming growth factor-b-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146:1077-1082.
51. Young MRI, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996; 67:333-338. (Pubitemid 26274122)
52. Bekeredjian-Ding I, Schafer M, Hartmann E, Pries R, Parcina M, Schneider P, et al. Tumour-derived prostaglandin E and transforming growth factor-b synergize to inhibit plasmacytoid dendritic cell-derived interferon-a. Immunology 2009; 128:439-450.
53. Strauss L, Volland D, Kunkel M, Reichert TE. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med Sci Monit 2005; 11:BR280-BR292. (Pubitemid 41224394)
54. Jeong YI, Kim SW, Jung ID, Lee JS, Chang JH, Lee CM, et al. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the janus-activated kinase-protein kinase Cd-STAT1 signaling pathway in interferon-g-stimulated murine dendritic cells. J Biol Chem 2009; 284:3700-3708.
55. Cheng CW, Shieh PC, Lin YC, Chen YJ, Lin YH, Kuo DH, et al. Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of g-interferon-induced JAK-PKC-d-STAT1 signaling in human oral cancer cells. J Agric Food Chem 2010; 58:887-894.
56. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009; 15:6348-6357.
57. Gasparoto TH, De Souza M, Benevides L, De Melo EJ, Costa MR, Damante JH, et al. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol Immunother 2010; 59:819-828.
58. + regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:744-752.
59. Schmidt EM, Wang CJ, Ryan GA, Clough LE, Qureshi OS, Goodall M, et al. CTLA-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol 2009; 182:274-282.
60. + T-cell lymphopenia-induced proliferation. Eur J Immunol 2009; 39:1544-1551.
61. Kolar P, Knieke K, Hegel JK, Quandt D, Burmester GR, Hoff H, et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum 2009; 60:123-132.
62. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-1717.
63. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010; 16:1042-1048.
64. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723. NEJMoa1003466.
65. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010; 16:2861-2871.
66. + cells to differentiate into antigen presenting dendritic cells. Clin Cancer Res 2001; 125:205-212. (Pubitemid 33662669)
67. + progenitor cells. Human Immunol 2001; 62:332-341. (Pubitemid 32298975)
68. + immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol 2000; 109:749-754. (Pubitemid 30637030)
69. + cells within human head and neck squamous cell carcinomas. J Immunol 1997; 159:990-996. (Pubitemid 127484255)
70. + cells. Int J Cancer 1997; 73:663-669. (Pubitemid 127483061)
71. + progenitor cell differentiation into endothelial cells. Int J Cancer 2004; 109:516-524. (Pubitemid 38339641)
72. 3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol 2010; 71:659-665.
73. + progenitor cells into dendritic cells. Otolaryngol Head Neck Surg 2009; 140:235-240.
74. + stem cells from human cord blood. In Vivo 2007; 21:493-498. (Pubitemid 46901408)
75. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-5701.
76. Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol 2009; 70:375-382.
77. Feinmesser R, Hardy B, Sadov R, Shwartz A, Chretien P, Feinmesser M. Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine. Arch Otolaryngol Head Neck Surg 2003; 129:874-881. (Pubitemid 36966434)
78. Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg 1994; 120:395-403. (Pubitemid 24129004)
79. Andrade Filho PA, Lopez-Albaitero A, Gooding W, Ferris RL. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother 2010; 33:83-91.
80. Farhadieh RD, Salardini A, Rees CG, Russell PJ, Yang JL, Smee R. Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. Ann Surg Oncol 2009; 16:2888-2894.
81. Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008; 99:1589-1594.
82. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, et al. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007; 450:287-295. (Pubitemid 46376559)
83. Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P, Fateh-Moghadam A. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 1996; 16:3117-3124. (Pubitemid 26390259)
84. Balermpas P, Hambek M, Seitz O, Rodel C, Weiss C. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol 2009; 185:775-781.
85. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010. [Epub ahead of print]